Inscripta has purchased Solana Biosciences, a San Diego company led by former Illumina veterans that specializes in genomics manufacturing operations.

Colorado-based Inscripta looks to advance genomics with a suite of gene-editing and tracking technologies for researchers. The acquisition provides “an elite, life-sciences product development and manufacturing pipeline for precision gene editing,” the company said in a press release.

Deal terms were not disclosed.

Tom Rosso, co-founder of Solana Biosciences and former vice president of operations at Illumina, will become vice president of operations at Inscripta.

Inscripta earlier this year raised $55.5 million in a series C round to commercialize its gene editing technology.